The partnership creates one of the largest global IV solutions manufacturing networks with combined production of an estimated 1.4 billion annual units and aims to bring additional supply chain resiliency and new innovation to the North American IV solutions market. Joint venture becomes part of a global manufacturing network with scale and redundancy Intends to add long-term supply resiliency and accelerate IV solutions new product development in North America Combines Otsuka Pharmaceutical Factory, Inc.
's expertise and global manufacturing scale with ICU Medical's strong North American production and distribution ICU Medical to provide commercial services to the joint venture Expected to become operationally effective in early Q2 2025 Full presentation available for view here SAN CLEMENTE, Calif. and TOKUSHIMA, Japan , Nov. 12, 2024 /PRNewswire/ -- ICU Medical, Inc.
(NASDAQ: ICUI ), a worldwide leader in the development, manufacture and sale of innovative medical devices, and Otsuka Pharmaceutical Factory, Inc. (OPF), global IV solutions manufacturing subsidiary of Otsuka Holdings Co., Ltd.
, together announce the creation of a joint venture to provide additional supply chain resiliency and innovation to the North American IV solutions market. The joint venture brings together OPF's expertise and global manufacturing scale—spanning 16 separate IV solutions production sites across Asia—with ICU Medical's strong North American production and distribution in the same catego.
